BioSpace News Archive

BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has entered into a debt settlement agreement (“Debt Settlement”) with a creditor, that has provided legal services to the Company, to extinguish

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced financial results for the second quarter ended June 30, 2020.

Agile Therapeutics, Inc., a women’s healthcare company, announced that Al Altomari, Chairman and Chief Executive Officer, will participate in a panel discussion as part of Maxim Group’s M-Vest Virtual Conference Series: Leading Innovators in Women’s Health, beginning at 10:00 a.m. Eastern Time on Thursday, August 13, 2020.

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the second quarter ended June 30, 2020. Loss from operations for the three months ended June 30, 2020 was $6.3 million.

Yield10 Bioscience, Inc., an agricultural bioscience company, reported financial results for the three and six months ended June 30, 2020.

Applied Molecular Transport (Nasdaq: AMTI), a clinical-stage biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2020.

Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2020.

Health Catalyst, Inc., a leading provider of data and analytics technology and services to healthcare organizations, reported financial results for the quarter ended June 30, 2020.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today reported financial results for the quarter ended June 30, 2020, and provided a business update.

Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported financial results for its second quarter ended June 30, 2020.